<?xml version="1.0" encoding="UTF-8"?>
<p>The reported improvement of CCA patients treated with MTX may be a pathway for understanding the uncertain pathogenesis of this emerging form of arthritis. The similarities in the clinical and pathogenic characteristics of CCA and RA make MTX an essential drug to evaluate in CCA. A better understanding of the treatment of CCA should provide further insights, not only in this disease, but in other forms of inflammatory arthritis, including RA.</p>
